VanEck非必需消費品TruSector主動型ETF TRUD 深 滬
等待開盤 06-25 09:30:00 美东时间
25.2903
+0.186
+0.74%
華盛通- 最 高25.75
- 今 開25.08
- 成交量 1.10万股
- 最 低 25.08
- 昨 收 25.1042
- 總市值 3085.42万
- 52周最高 27.475
- 市盈率 靜 --
- 換手率 0.90%
- 52周最低 22.8345
- 委 比 0.00%
- 總股本 122.00万
- 歷史最高 27.4545
- 量 比 0.26
- 振 幅 2.67%
- 歷史最低 22.8345
- 每 手 1
- 風險率 0.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Merck And Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Trial After Trodelvy–KEYTRUDA Combination Fails To Achieve Statistically Significant Progression-Free Survival Benefit In First-Line Metastatic NSCLC
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (NASDAQ:GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead's
06-09 04:31
FDA Approves Agilent Technologies' Expanded Use Of PD-L1 IHC 22C3 pharmDx, Code GE006,
Approval expands PD-L1 testing onto an automated workflow to support treatment decisions with KEYTRUDA® (pembrolizumab)¹,²
06-03 04:17
Moderna And Merck Present 5-Year Data For Intismeran Autogene in Combination With KEYTRUDA In Patients With High-Risk Stage III/IV Melanoma
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence or death and a
06-01 20:05
European Medicines Agency's Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Approval Of Merck's KEYTRUDA In Combination With Padcev To Treat Resectable Muscle-Invasive Bladder Cancer
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending
05-22 19:57
BRIEF-EMA's CHMP Recommends Extension To Marketing Authorisation For Wegovy
BRIEF-EMA's CHMP Recommends Extension To Marketing Authorisation For Wegovy May 22 (Reuters) - EMA's CHMP: EMA'S CHMP: RECOMMENDED EXTENSION TO MARKETING AUTHORISATION FOR WEGOVY CHMP: RECOMMENDS EXTENSION TO MARKETING AUTHORISATION FOR WEGOVY TO ADD DAILY ORAL TABLET AS ALTERNATIVE FORMULATION TO W
05-22 19:01
PDS Biotech outlines VERSATILE-003 amendment targeting interim PFS with approximately 250 patients
Earnings Call Insights: PDS Biotechnology Corporation (PDSB) Q1 2026 Management view Dr. Frank Bedu-Addo (President, CEO & Director) said the quarter’s “major focus was on advancing our clinical progr...
05-13 22:11
Erasca Announces Clinical Trial Collaboration And Supply Agreement With Merck To Evaluate ERAS-0015 In Combination With Keytruda
This agreement supports a clinical proof-of-concept study, AURORAS-1, evaluating the pan-RAS molecular glue ERAS-0015 in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, for the treatment of
05-11 19:03
FDA grants priority review to Merck’s Keytruda-Padcev for cisplatin-eligible bladder cancer
FDA grants priority review to Merck’s Keytruda-Padcev for cisplatin-eligible bladder cancer FDA granted priority review for Merck sBLA seeking KEYTRUDA, KEYTRUDA QLEX use with Padcev in perioperative treatment of cisplatin-eligible muscle-invasive bladder cancer. PDUFA target action date set for Aug
04-20 18:48
Adagene's Muzastotug Triplet Regimens Show Superior Response Rates In HCC And MSS CRC, Highlighting Improved Anti-CTLA-4 Tumor-Targeting At AACR 2026
Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively by Investigator per
04-18 04:03
Merck Says EU Approves KEYTRUDA, In Combination With Paclitaxel, With Or Without Bevacizumab, For Treatment Of Platinum-Resistant Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma In Adults
The KEYTRUDA regimen is the first and only PD-1 inhibitor-based treatment approved in the European Union for these patientsApproval supported by data from the Phase 3 KEYNOTE-B96 trial in which the KEYTRUDA regimen
04-02 18:48
